Comerica Bank Has $1.36 Million Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Comerica Bank lifted its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 71.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 37,548 shares of the specialty pharmaceutical company’s stock after purchasing an additional 15,585 shares during the quarter. Comerica Bank’s holdings in Supernus Pharmaceuticals were worth $1,358,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Barclays PLC raised its stake in shares of Supernus Pharmaceuticals by 88.3% in the third quarter. Barclays PLC now owns 108,788 shares of the specialty pharmaceutical company’s stock valued at $3,393,000 after purchasing an additional 51,005 shares in the last quarter. Franklin Resources Inc. grew its position in Supernus Pharmaceuticals by 7.6% in the third quarter. Franklin Resources Inc. now owns 29,981 shares of the specialty pharmaceutical company’s stock valued at $987,000 after acquiring an additional 2,121 shares during the period. Empowered Funds LLC bought a new stake in Supernus Pharmaceuticals in the fourth quarter valued at $1,498,000. Smartleaf Asset Management LLC grew its position in Supernus Pharmaceuticals by 219.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company’s stock valued at $47,000 after acquiring an additional 870 shares during the period. Finally, JPMorgan Chase & Co. grew its position in Supernus Pharmaceuticals by 40.6% in the third quarter. JPMorgan Chase & Co. now owns 253,396 shares of the specialty pharmaceutical company’s stock valued at $7,901,000 after acquiring an additional 73,118 shares during the period.

Insider Activity

In other news, SVP Jonathan Rubin sold 927 shares of the firm’s stock in a transaction on Friday, February 21st. The stock was sold at an average price of $39.15, for a total value of $36,292.05. Following the completion of the sale, the senior vice president now directly owns 7,853 shares in the company, valued at approximately $307,444.95. This trade represents a 10.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. 9.30% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on SUPN. Cantor Fitzgerald reiterated a “neutral” rating and issued a $36.00 price target on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th. StockNews.com cut Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday.

Supernus Pharmaceuticals Stock Performance

Shares of SUPN stock opened at $31.70 on Monday. Supernus Pharmaceuticals, Inc. has a 52 week low of $25.53 and a 52 week high of $40.28. The stock has a market capitalization of $1.77 billion, a PE ratio of 29.63 and a beta of 0.74. The stock’s fifty day moving average is $31.86 and its 200-day moving average is $34.90.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.